Randomized, Double-Masked, Pilot Study of Netarsudil 0.02% Ophthalmic Solution for Treatment of Corneal Edema in Fuchs Dystrophy - PubMed (original) (raw)
Randomized Controlled Trial
doi: 10.1016/j.ajo.2021.03.006. Epub 2021 Mar 15.
Affiliations
- PMID: 33737034
- DOI: 10.1016/j.ajo.2021.03.006
Randomized Controlled Trial
Randomized, Double-Masked, Pilot Study of Netarsudil 0.02% Ophthalmic Solution for Treatment of Corneal Edema in Fuchs Dystrophy
Marianne O Price et al. Am J Ophthalmol. 2021 Jul.
Abstract
Purpose: To evaluate off-label use of netarsudil 0.02% for treatment of corneal edema associated with Fuchs dystrophy.
Design: Prospective, randomized clinical trial.
Methods: Twenty-nine subjects with symptomatic Fuchs dystrophy were enrolled and randomized to use netarsudil or placebo eye drops once daily for 3 months. The primary outcomes were the change in central corneal thickness between baseline and 1 month and between baseline and 3 months. Secondary outcomes included change in scotopic corrected distance visual acuity (CDVA) at 3 months and change in scores on a visual disability questionnaire validated for use with Fuchs dystrophy.
Results: Compared with use of placebo, use of netarsudil produced significant reduction in central corneal thickness at 1 month (mean difference, -20 µm; 95% confidence interval, -32 to -9 µm) and 3 months (mean difference, -26 µm; 95% confidence interval, -39 to -12 µm) and significant improvement in scotopic CDVA at 3 months (mean difference +1.6 lines; 95% confidence interval, 0.2-3.0 lines). Scores on the visual disability questionnaire did not change significantly in either arm or differ significantly between arms. One subject assigned to netarsudil had baseline epithelial bullae and withdrew from the study because of disabling glare.
Conclusions: Use of netarsudil was associated with reduction of corneal edema and improvement in scotopic CDVA in Fuchs dystrophy patients. Further study is needed to more fully assess patient satisfaction and visual acuity under various lighting conditions and to compare use of netarsudil with other treatment options such as endothelial keratoplasty.
Copyright © 2021 Elsevier Inc. All rights reserved.
Similar articles
- Hyperosmolar Eye Drops for Diurnal Corneal Edema in Fuchs' Endothelial Dystrophy: A Double-Masked, Randomized Controlled Trial.
Zander DB, Böhringer D, Fritz M, Grewing V, Maier PC, Lapp T, Reinhard T, Wacker K. Zander DB, et al. Ophthalmology. 2021 Nov;128(11):1527-1533. doi: 10.1016/j.ophtha.2021.04.015. Epub 2021 Apr 20. Ophthalmology. 2021. PMID: 33892048 Clinical Trial. - Descemet Stripping Only Supplemented With Topical Ripasudil for Fuchs Endothelial Dystrophy 12-Month Outcomes of the Sydney Eye Hospital Study.
Moloney G, Garcerant Congote D, Hirnschall N, Arsiwalla T, Luiza Mylla Boso A, Toalster N, D'Souza M, Devasahayam RN. Moloney G, et al. Cornea. 2021 Mar 1;40(3):320-326. doi: 10.1097/ICO.0000000000002437. Cornea. 2021. PMID: 32740006 - Rho kinase (ROCK) inhibitors in the management of corneal endothelial disease.
Syed ZA, Rapuano CJ. Syed ZA, et al. Curr Opin Ophthalmol. 2021 May 1;32(3):268-274. doi: 10.1097/ICU.0000000000000748. Curr Opin Ophthalmol. 2021. PMID: 33606407 Review. - New therapeutic modality for corneal endothelial disease using Rho-associated kinase inhibitor eye drops.
Koizumi N, Okumura N, Ueno M, Kinoshita S. Koizumi N, et al. Cornea. 2014 Nov;33 Suppl 11:S25-31. doi: 10.1097/ICO.0000000000000240. Cornea. 2014. PMID: 25289721 Review.
Cited by
- Ocular effects of Rho kinase (ROCK) inhibition: a systematic review.
Lin JB, Harris JM, Baldwin G, Goss D, Margeta MA. Lin JB, et al. Eye (Lond). 2024 Sep 16. doi: 10.1038/s41433-024-03342-4. Online ahead of print. Eye (Lond). 2024. PMID: 39285241 Review. - Guttae Morphology After Cultured Corneal Endothelial Cell Transplant in Fuchs Endothelial Corneal Dystrophy.
Tomioka Y, Ueno M, Yamamoto A, Numa K, Tanaka H, Kitazawa K, Toda M, Koizumi N, Tanaka M, Hamuro J, Sotozono C, Kinoshita S. Tomioka Y, et al. JAMA Ophthalmol. 2024 Sep 1;142(9):818-826. doi: 10.1001/jamaophthalmol.2024.2718. JAMA Ophthalmol. 2024. PMID: 39052247 - Therapeutic future of Fuchs endothelial corneal dystrophy: An ongoing way to explore.
Liu JX, Chiang TL, Hung KF, Sun YC. Liu JX, et al. Taiwan J Ophthalmol. 2024 Jan 5;14(1):15-26. doi: 10.4103/tjo.TJO-D-23-00115. eCollection 2024 Jan-Mar. Taiwan J Ophthalmol. 2024. PMID: 38654984 Free PMC article. Review. - Reticular Bullous Epithelial Corneal Edema after Netarsudil Use for Elevated Intraocular Pressure with Concurrent Fuchs Endothelial Corneal Dystrophy: A Case Report.
Park KS, Lieu AC, Ang MJ, Afshari NA. Park KS, et al. Case Rep Ophthalmol. 2024 Apr 17;15(1):369-373. doi: 10.1159/000538119. eCollection 2024 Jan-Dec. Case Rep Ophthalmol. 2024. PMID: 38633448 Free PMC article. - Topical netarsudil for the treatment of primary corneal endothelial degeneration in dogs.
Casanova MI, Park S, Mayes MA, Roszak K, Ferneding M, Echeverria N, Bowman MAW, Michalak SR, Ardon M, Wong S, Le SM, Daley N, Leonard BC, Good KL, Li JY, Thomasy SM. Casanova MI, et al. Sci Rep. 2024 Mar 14;14(1):6238. doi: 10.1038/s41598-024-56084-4. Sci Rep. 2024. PMID: 38485975 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources